大阪大学 · 医学
Hirofumi Yamamoto教授の研究室は、消化器がんの発症・進行メカニズムの解明と、がん治療の効果を高める新規標的の同定を柱としています。特に、SurvivinやPLOD2といったがん関連タンパク質の機能と予後への影響、ならびにKRAS変異がもたらすマイクロRNAの変化と治療抵抗性の関連を分子レベルで解明しています。画像診断による早期発見と、がん細胞の生存機構を標的にした治療戦略の開発が、今後の臨床応用に向けた重要な柱です。
Figures are computed from collected data and may differ slightly.
PSVT is a more frequent complication of laparoscopic splenectomy than previously reported but can be treated safely following early detection by CT with contrast.
Survivin has multiple functions including cytoprotection, inhibition of cell death, and cell-cycle regulation, especially at the mitotic process stage, all of which favor cancer survival. Many studies on clinical specimens have shown that survivin expression is invariably up-regulated in human cancers and is associated with resistance to chemotherapy or radiation therapy, and linked to poor prognosis, suggesting that cancer cells survive with survivin. It is also reported that survivin inhibitio
KRAS mutations are a major cause of drug resistance to molecular-targeted therapies. Aberrant epidermal growth factor receptor (EGFR) signaling may cause dysregulation of microRNA (miRNA) and gene regulatory networks, which leads to cancer initiation and progression. To address the functional relevance of miRNAs in mutant KRAS cancers, we transfected exogenous KRAS(G12V) into human embryonic kidney 293 and MRC5 cells with wild-type KRAS and BRAF genes, and we comprehensively profiled the dysregu
PLOD2 is a potential novel prognostic factor for HCC patients following surgery.
Open papers in the app to read, cite, and organize with AI.
